The Latest Breaking News from Lilly

Investors seeking growth and dividend income in the healthcare sector may want to consider Eli Lilly, Gilead Sciences, and Amgen, which have delivered impressive returns and boast strong pipelines and strategic moves.

Pharmaceutical giant Eli Lilly and Company (LLY) is on an impressive run after winning Food and Drug Administration approval for a new eczema drug called Ebglyss. As the company expands its reach in the diabetes, obesity, and eczema markets, is it a must-have in your healthcare portfolio? Read on to…

Hims stock rallied almost 22% over two days on enthusiasm after the FDA said it will allow compounded versions of Lilly's obesity drug.

THE Health Secretary has said unemployed people will be given weight-loss injections as part of a UK Government drive to “get them back to…

Hims stock popped Monday after the FDA reportedly said it would reconsider its decision to bar compounders from selling knockoff tirzepatide.

Amgen stock dipped Monday after an analyst downgraded shares, saying the opportunity for its weight-loss drug is already baked into the stock.

Viking Therapeutics stock is on the rise as the battle to develop new weight-loss drugs heats up. Here's what's at stake for the pharma giants fighting for position.

Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain.

The list of 100 executives spans the globe.